The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
In this article
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
Novo Nordisk isn’t catching a break this year.
Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed to match the weight loss of Eli Lilly
’s Zepbound in a phase three trial.
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk scivola in Borsa (-8%) dopo dati deludenti per Cagrisema - Notizie - Ansa.it
Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Nuovo farmaco dimagrante di Novo Nordisk batte la ritirata, Eli Lilly avanza
Cade Novo Nordisk a Copenaghen, il farmaco anti-obesità è meno efficace del rivale americano
